Compound Evidence File
#EC-2026-0881
MK-677 (Ibutamoren) Raw
Filed under Raw Materials. The bureau holds 125 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 16 Apr 2026 | 19 Jul 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Jan 2026 | 5 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 8 Mar 2026 | 6 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Jun 2026 | 11 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Jan 2026 | 19 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 17 May 2026 | 27 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 9 May 2026 | 8 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Dec 2025 | 20 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 20 May 2026 | 2 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Apr 2026 | 11 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Mar 2026 | 14 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Jul 2026 | 9 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Jan 2026 | 3 Mar 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 10.0 | 10.0 | 10.0 | 14 Jan 2025 | 14 Jan 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Dec 2025 | 2 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Apr 2026 | 10 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Feb 2026 | 16 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Apr 2026 | 23 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Apr 2026 | 12 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 8 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Jun 2026 | 22 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 14 Mar 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 9.2 | 9.2 | 9.3 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.4 | 6.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.4 | 7.2 | 10.0 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.2 | 7.2 | 9.2 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.2 | 6.3 | 10.0 | 21 May 2026 | 21 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 8.0 | 8.0 | 8.0 | 6 May 2025 | 6 May 2025 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 7.9 | 7.9 | 7.9 | 27 Feb 2025 | 27 Feb 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 14 | 7.7 | 5.6 | 9.1 | 20 Jun 2025 | 20 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 6.8 | 6.8 | 6.8 | 14 Jan 2025 | 14 Jan 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 6.6 | 6.6 | 6.6 | 13 Feb 2025 | 13 Feb 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 11 | 6.2 | 4.0 | 9.5 | 13 Jun 2025 | 26 Jan 2026 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 5.8 | 5.8 | 5.8 | 20 Jun 2025 | 20 Jun 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 5.3 | 5.3 | 5.3 | 7 May 2025 | 7 May 2025 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 1 | 4.1 | 4.1 | 4.1 | 16 Mar 2025 | 16 Mar 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.6 | 0.6 | 0.6 | 25 Apr 2025 | 25 Apr 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.0 | 0.0 | 0.0 | 27 Feb 2025 | 27 Feb 2025 |
Open any subject to view the batch-level evidence for MK-677 (Ibutamoren) Raw alone.